PrairieView Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PrairieView Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-460	Closed	-$48K	–	504
2022 Q1	$48K	Hold	460	–	–	0.01%	205
2021 Q4	$50K	Buy	+460	New	+$50.2K	0.01%	208

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PrairieView Partners's HZNP Position: Q2 2022 in Review

PrairieView Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 460 shares — an estimated $48K sold.

PrairieView Partners first reported a position in HZNP in Q4 2021 and held it in 2 quarters. The position peaked at $50K in Q4 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

PrairieView Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
PrairieView Partners sold 460 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $48K.
PrairieView Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 2 quarters.
PrairieView Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $50K in Q4 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on PrairieView Partners's 13F filing for Q2 2022, filed 22 Jul 2022.